Learn about our work and hear what our clients have to say.
![](/wp-content/uploads/2021/05/NKarta_Case_Study-FINAL.png)
Nkarta Collaboration Achieves Cost Effective Manufacturing in Tight Timelines
Find out more about why Nkarta chose CCRM as its partner for clinical phase manufacturing of a natural killer cell product.
“We’ve found an ongoing partner [in CCRM]” – Dr. Ralph Brandenberger, SVP Technical Operations, Nkarta
![](/wp-content/uploads/2021/05/DiscGenics_Case_Study-FINAL-Updated-May-3-2021-1.png)
DiscGenics Collaboration Successfully Develops Allogeneic Therapy to Enable Efficient Manufacturing
Learn about how DiscGenics worked with CCRM to establish a novel process.
“[The team] really helped us get to where we are today.” – Dr. Lara Ionescu Silverman, PhD, Senior Director, Research and Development, DiscGenics
![](/wp-content/uploads/2021/05/Avectas-_Case_Study.png)
Collaborative Relationship Allows Avectas to Accelerate the Translation of SOLUPORE™ into the Clinic
Learn how Avectas, a cell engineering technology company, worked with CCRM to develop a unique intracellular delivery platform to enable ex vivo cell-based therapies.
“[CCRM’s] culture and adaptive nature, flexibility and communication were excellent.” – Edel O’Toole, Senior Director Project & Vendor Management, Avectas
![The Cystic Fibrosis (CF) Canada Program in Individualized Therapy (CFIT)](/wp-content/uploads/2020/11/Thumbnail-The-CF-Canada-Program-in-Individualized-Therapy.png)
The Cystic Fibrosis (CF) Canada Program in Individualized Therapy (CFIT)
Learn how our team collaborated with an academic lab at SickKids to establish a bank of 100 patient-derived iPSC lines and isogenic controls.
“CCRM has shared valuable expertise with our team, benefiting the project overall.”
– Dr. Christine Bear, The Hospital for Sick Children
![Process Development for Scaled-up hESC/hiPSC Manufacturing](/wp-content/uploads/2020/11/Thumbnail-PD-for-Scaled-up-hESC-hiPSC-Manufacturing.png)
Process Development for Scaled-Up hESC/hiPSC Manufacturing
Read about an optimized 14-day manufacturing workflow that produces >1010 cells.
![Manufacturing of Pluripotent Stem Cell-Derived Cardiomyocytes for Pre-Clinical Animal Studies](/wp-content/uploads/2020/11/Thumbnail-Manufacturing-of-PSC-Derived-Cardiomyocytes-for-Pre-Clinical-Animal-Studies.png)
Manufacturing of Pluripotent Stem Cell-Derived Cardiomyocytes for Pre-Clinical Animal Studies
Find out how CCRM worked with a member of the local academic community to translate a cell therapy protocol from bench-scale to bioreactor.
![Animal Component Free (ACF) Media Development for Cell Therapies](/wp-content/uploads/2020/11/Thumbnail-ACF-Media-Development-for-Cell-Therapies.png)
Animal Component Free (ACF) Media Development for Cell Therapies
Understand how ACF media can achieve comparable performance to serum containing media.